secwatch.observer — SEC 8-K summary
======================================

Issuer:     BridgeBio Pharma, Inc. (BBIO)
CIK:        0001743881
Form:       8-K
Filed at:   2023-08-03T23:59:59+00:00
Accession:  0000950170-23-037590
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BridgeBio Q2 net loss $157.9M; acoramidis Phase 3 ATTR-CM meets primary endpoint, NDA planned by end 2023
--------------------------------------------------------------------------------

- Phase 3 ATTRibute-CM of acoramids achieved highly significant primary endpoint, Win Ratio 1.8 (p<0.0001); NDA filing planned by end 2023.
- Revenue $1.6M in Q2 vs $73.7M prior year due to $70.2M one-time license in 2022; net loss $157.9M.
- Cash & equivalents $353.2M; mgmt expects $300-350M to support acoramidis launch.
- Announced positive infigratinib Phase 2 results in achondroplasia; mean AHV +3.38 cm/year.
- BBP-418 Phase 3 FORTIFY trial dosed first patient; FDA discussion supports accelerated approval potential.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1743881/000095017023037590/0000950170-23-037590-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1743881/000095017023037590/bbio-20230803.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-037590

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer